Literature DB >> 19426951

2009 Alzheimer's disease facts and figures.

.   

Abstract

Alzheimer's disease (AD) is the sixth leading cause of all deaths in the United States, and the fifth leading cause of death in Americans aged 65 and older. Whereas other major causes of death have been on the decrease, deaths attributable to AD have been rising dramatically. Between 2000 and 2006, heart-disease deaths decreased nearly 12%, stroke deaths decreased 18%, and prostate cancer-related deaths decreased 14%, whereas deaths attributable to AD increased 47%. An estimated 5.3 million Americans have AD; the approximately 200,000 persons under age 65 years with AD comprise the younger-onset AD population. Every 70 seconds, someone in America develops AD; by 2050, this time is expected to decrease to every 33 seconds. Over the coming decades, the "baby-boom" population is projected to add 10 million people to these numbers. In 2050, the incidence of AD is expected to approach nearly a million people per year, with a total estimated prevalence of 11 to 16 million people. Significant cost implications related to AD and other dementias include an estimated $148 billion annually in direct (Medicare/Medicaid) and indirect (e.g., decreased business productivity) costs. Not included in these figures is the $94 billion in unpaid services to individuals with AD provided annually by an estimated 10 million caregivers. Mild cognitive impairment (MCI) is an important component in the continuum from healthy cognition to dementia. Understanding which individuals with MCI are at highest risk for eventually developing AD is key to our ultimate goal of preventing AD. This report provides information meant to increase an understanding of the public-health impact of AD, including incidence and prevalence, mortality, lifetime risks, costs, and impact on family caregivers. This report also sets the stage for a better understanding of the relationship between MCI and AD.

Entities:  

Mesh:

Year:  2009        PMID: 19426951     DOI: 10.1016/j.jalz.2009.03.001

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  121 in total

Review 1.  Beyond the signaling effect role of amyloid-ß42 on the processing of APP, and its clinical implications.

Authors:  Debomoy K Lahiri; Bryan Maloney
Journal:  Exp Neurol       Date:  2010-05-05       Impact factor: 5.330

Review 2.  The Alzheimer's disease neuroimaging initiative: progress report and future plans.

Authors:  Michael W Weiner; Paul S Aisen; Clifford R Jack; William J Jagust; John Q Trojanowski; Leslie Shaw; Andrew J Saykin; John C Morris; Nigel Cairns; Laurel A Beckett; Arthur Toga; Robert Green; Sarah Walter; Holly Soares; Peter Snyder; Eric Siemers; William Potter; Patricia E Cole; Mark Schmidt
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 3.  Impaired regulation of synaptic actin cytoskeleton in Alzheimer's disease.

Authors:  Peter Penzes; Jon-Eric Vanleeuwen
Journal:  Brain Res Rev       Date:  2011-01-26

4.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

5.  Preventing cognitive decline in older African Americans with mild cognitive impairment: design and methods of a randomized clinical trial.

Authors:  Barry W Rovner; Robin J Casten; Mark T Hegel; Benjamin E Leiby
Journal:  Contemp Clin Trials       Date:  2012-03-02       Impact factor: 2.226

6.  The aging physician.

Authors:  Linda Lee; Wayne Weston
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

7.  The effect of dementia on medication use and adherence among Medicare beneficiaries with chronic heart failure.

Authors:  Gail B Rattinger; Sarah K Dutcher; Pankdeep T Chhabra; Christine S Franey; Linda Simoni-Wastila; Stephen S Gottlieb; Bruce Stuart; Ilene H Zuckerman
Journal:  Am J Geriatr Pharmacother       Date:  2012-01-20

8.  Functional connectivity variations in mild cognitive impairment: associations with cognitive function.

Authors:  S Duke Han; Konstantinos Arfanakis; Debra A Fleischman; Sue E Leurgans; Elizabeth R Tuminello; Emily C Edmonds; David A Bennett
Journal:  J Int Neuropsychol Soc       Date:  2011-10-18       Impact factor: 2.892

Review 9.  Alzheimer's disease: strategies for disease modification.

Authors:  Martin Citron
Journal:  Nat Rev Drug Discov       Date:  2010-05       Impact factor: 84.694

10.  Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease.

Authors:  H Fillit; J Cummings; P Neumann; T McLaughlin; P Salavtore; C Leibman
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.